--- title: "Satellos Bioscience to Join Guggenheim Securities Emerging Outlook Biotech Summit" description: "Satellos Bioscience Inc. will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in New York City on February 12, 2026, at 10 a.m. ET. The event will be " type: "news" locale: "en" url: "https://longbridge.com/en/news/275453193.md" published_at: "2026-02-10T12:01:53.000Z" --- # Satellos Bioscience to Join Guggenheim Securities Emerging Outlook Biotech Summit > Satellos Bioscience Inc. will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in New York City on February 12, 2026, at 10 a.m. ET. The event will be available via live webcast, with a replay accessible afterward. The leadership team will also hold one-on-one investor meetings during the conference. Interested investors can contact their Guggenheim representative or email Satellos for scheduling. Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL), a clinical-stage biotechnology company focused on muscle repair and regeneration, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in New York City on Thursday, February 12, 2026, at 10 a.m. ET. The fireside chat will be available via live webcast on the Events and Presentations page in the Investors section of the company’s website, with a replay accessible following the event. Members of the Satellos leadership team will also be available for one-on-one investor meetings during the conference. Investors interested in scheduling a meeting may contact their Guggenheim representative or email Satellos at ir@satellos.com. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210502722) on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### Related Stocks - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) - [LABD.US - Direxion S&P Biotech Bear 3X](https://longbridge.com/en/quote/LABD.US.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [MSLE.US - Satellos Bioscience](https://longbridge.com/en/quote/MSLE.US.md) - [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Fate Therapeutics 第四季度財報總結及主要內容 | Fate Therapeutics（納斯達克代碼：FATE）於 2026 年 2 月 26 日公佈了第四季度財報，實際每股收益（EPS）為-0.27，未能達到預期。與去年相比，收入減少了 491,000 美元。在上一個季度，公司每股收益超出 | [Link](https://longbridge.com/en/news/277057214.md) | | Artisan Partners Limited Partnership 增加了其在 Twist Bioscience Corporation $TWST 的股份 | Artisan Partners Limited Partnership 在第三季度將其在 Twist Bioscience Corporation (NASDAQ:TWST) 的持股增加了 26.7%，目前持有 6,410,900 股，價 | [Link](https://longbridge.com/en/news/277163890.md) | | 探討 Belite Bio 的盈利預期 | Belite Bio (NASDAQ:BLTE) 將於 2026 年 3 月 2 日公佈季度財報，分析師預計每股收益（EPS）為-0.55 美元。投資者期待在之前每股收益未達預期導致股價下跌 9.87% 後，能夠獲得積極的指引。目前，股票交 | [Link](https://longbridge.com/en/news/277224746.md) | | 關鍵事實：ImmunityBio 已完成第二階段試驗的招募工作；電話會議已安排 | ImmunityBio 已經提前完成了其第二階段 Quilt 2.005 試驗的招募，該試驗評估 Anktiva 和 BCG 對早期膀胱癌的療效，顯示出改善的無癌率。ImmunityBio, Inc. 將於 2026 年 3 月 3 日下午 | [Link](https://longbridge.com/en/news/277243866.md) | | Nuvation Bio 的盈利概況 | Nuvation Bio（紐約證券交易所代碼：NUVB）將於 2026 年 3 月 2 日公佈季度財報，分析師預計每股收益（EPS）為-0.07 美元。儘管最近出現了每股收益未達預期的情況，導致股價下跌 6.58%，但該公司過去一年股價仍上 | [Link](https://longbridge.com/en/news/277235801.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.